NEMUS  Bioscience  OTCQB:  NMUS  

2  

Forward  Looking  Statement  

This  presenta-on  contains   “forward-­‐looking   statements”  within   the  meaning  of   the  “safe  harbor”  provisions  of  the  Private  Securi-es  Li-ga-on  Reform  Act  of  1995.  All  of  the  statements  in  this  presenta-on,  whether  wriGen  or  oral,   that   refer   to   expected   or   an-cipated   future   ac-ons   and   results   of   NEMUS   Bioscience,   Inc.   (NEMUS)   are  forward-­‐looking   statements.   These   forward-­‐looking   statements   reflect   the   beliefs   and   expecta-ons   of   the  management  of  NEMUS  as  of  the  date  of  this  presenta-on.  NEMUS  cannot  give  any  assurance  that  such  forward-­‐looking  statements  will  prove  to  be  correct.  The  reader  is  cau-oned  not  to  place  undue  reliance  on  these  forward-­‐looking  statements.        The  informa-on  provided  in  this  presenta-on  does  not  iden-fy  or  include  any  risk  or  exposures,  of  NEMUS  that  would  materially   adversely   affect   the   performance   or   risk   of   the   company.   For   a   descrip-on   of   the   risks   and  uncertain-es  related  to  the  business  of  NEMUS,  see  our  Annual  Report  on  Form  10-­‐K    filed  with  the  Securi-es  and  Exchange  Commission    and  our  subsequent  periodic  reports  filed  with  the  Securi-es  and  Exchange  Commission.        All   informa-on   contained   in   this   presenta-on   is   provided   as   of   the   date   of   the   presenta-on   and   is   subject   to  change   without   no-ce.   Neither   NEMUS,   nor   any   other   person   undertakes   any   obliga-on   to   update   or   revise  publicly   any   of   the   forward-­‐looking   statements   set   out   herein,  whether   as   a   result   of   new   informa-on,   future  events  or  otherwise,  except  as  required  by  law.  This  presenta-on  does  not  convey  an  offer  of  any  type  and  is  not  intended   to   be,   and   should   not   be   construed   as,   an   offer   to   sell,   or   the   solicita-on   of   an   offer   to   buy,   any  securi-es  of  NEMUS.  

3  

OTCQB   NMUS  

Price  (9/2/16)   $0.56  

Market  Cap  (8/31/16)   $11.15  M  

Shares  Outstanding   19.9  M  common  &  4500  PS,  25.5  M  if  100%  converted  

%  Ownership  by  Directors  &  Employees  

31.4%  shares  1.2  M  op-ons    

Warrants  Outstanding   10.9  M  (Avg.  Strike  @  $1.15)  

Founded   2012  

Base  of  Opera-ons   Costa  Mesa,  California    &  Oxford,  Mississippi  

Company  Overview  

NEMUS  Bioscience  is  a  publicly  traded,  life-­‐science  biotech  company,  focused  on  developing  regulatory-­‐approved,  cannabinoid-­‐based  therapies,  for  a  

spectrum  of  diseases,  especially  those  of  unmet  medical  need  

4  

NEMUS  Value  ProposiIon  

•  NEMUS  is  focused  on  developing  cannabinoid  molecules  for  the  treatment  and  management  of  acute  and  chronic  diseases,  especially  those  of  unmet  medical  need  

•  NEMUS  is  the  sole  development  and  commercializaIon  partner  of  the  University  of  Mississippi,  drawing  on  48  years  of  intellectual  capital  in  cannabinoid  chemistry  and  physiology  from  the  only  enIty  with  a  Federal  license  to  directly  study  cannabinoids  

•  NEMUS  is  advancing  therapeuIcs  for  medical  applicaIons  in  global  mulI-­‐billion  dollar  markets  including:  

ü   A  cannabinoid  franchise  in  ophthalmology  in  glaucoma  and  re6nal  diseases    

ü  Pallia6ve  care  in  oncology  (CINV  and  CIPN)    

ü  An6-­‐infec6ves,  especially  in  strains  developing  resistance  to  an6bio6cs  (MRSA)  

•  Proprietary  product  pipeline  led  by  a  pro-­‐drug  of  tetrahydrocannibinol  (THC)  and  novel  deriva-ves  of  cannabidiol  (CBD)  

•  NEMUS  management  team  has  proven  track-­‐record  in  drug  research,  pharmaceu-cal  &  biotech  development,  and  public  company  experience  on  a  global  scale  

5  

NEMUS  Milestones  

Recent  Milestones  •  December  2015:  NEMUS  in-­‐licenses  CBD  deriva-ves  from  UM  and  ini-ates  research  into  chemotherapy  induced  

peripheral  neuropathy  (CIPN)  

•  January  2016:  NEMUS  announces  valida-on  of  NB1111  data  in  glaucoma  with  45%  decline  in  IOP  as  NEMUS  becomes  leading  cannabinoid  drug  developer  in  ophthalmology  

•  January  2016:  NEMUS  announces  ini-a-on  of  development  program  for  chemotherapy-­‐induced  nausea  and  vomi-ng  (CINV)  and  pre-­‐NDA  mee-ng  with  the  FDA  

•  February  2016:  NEMUS  signs  agreement  with  AMRI  to  manufacture  proprietary  API  for  glaucoma  (NB1111)  and  CINV  (NB1222)  programs  

•  June  2016:  NEMUS  announces  successful  iden-fica-on  of  CBD-­‐like  candidate  molecule  (NB2111)  with  significant  analgesic  ac-vity  versus  morphine  in  validated  animal  CIPN  study;  

•     •  July  2016:  Glaucoma  study  confirms  >40%  decline  in  IOP  correla-ng  decline  to  THC  concentra-on  in  IOP-­‐regula-ng  

ocular  -ssues;  study  confirms  presence  of  THC  in  all  major  ocular  compartments;  no  THC  found  in  plasma  

•  July  2016:  patent  issued  in  Australia  for  NB1111/NB1222  THC  prodrug  

•  August  2016:  murine  tac-le  allodynia  study  reveals  dose-­‐escala-on  of  CBD  deriva-ve  molecule  delivers  comparable  analgesia  safely  in  validated  pain  model  versus  morphine  

6  

June,  2016:  Nemus  and  Teewinot  plan  to  collaborate  to  “disrupt”  the  cannabinoid  market  •  Nemus  is  dedicated  to  “disrup-ng”  the  cannabinoid    space  by  introducing  prodrug  and  

analogue  versions  of  cannabinoids  that  are  designed  to  improve  efficacy  and  safety  versus  naturally  derived  counterparts  

•  Nemus  signed  a  leGer  of  intent  with  Teewinot  Life  Science  Corp.  to  manufacture  biosynthe-cally  produced  cannabinoid  molecules  based  on  Nemus’  proprietary  prodrug  technology  

•  We  believe  biosynthe-cally  produced  cannabinoids  offer  significant  cost-­‐efficient  manufacturing  and  enhanced  produc-on  scheduling  not  associated  with  plant-­‐derived  or  chemically  synthesized  produc-on  

•  Teewinot’s  wholly  owned  subsidiary,  Full  Spectrum  Laboratories,  Ltd.,  has  been  issued  mul-ple  patents  related  to  biosynthe-c  methods  and  produc-on  capabili-es  

•  This  collabora-on  will  permit  Nemus  to  produce  both  major  (THC  and  CBD)  and  minor  cannabinoids  for  development  as  both  poten-al  second-­‐  and  third-­‐genera-on  cannabinoid-­‐based  therapies  

   

7  

NEMUS  Cannabinoid  Prodrug  Programs    Hold  CompeIIve  Advantages  Orally  administered  cannabinoids  (both  pill  and  spray  delivery  mechanisms)  hold  a  variety  of  disadvantages  for  paIents:  •  Poor  bioavailability  vs  other  routes  of  administraIon  •  Irregular  pharmacokineIcs  secondary  to  GI  absorpIon  •  SuscepIble  to  significant  first-­‐pass  metabolism  by  the  liver  

 –  “Due  to  extensive  first-­‐pass  metabolism  and  high  lipid  

solubility,  a  frac-on  of  the  drug  reaches  the  circula-on”1      

–  “The  pharmacologic  effects  of  Marinol  are  dose-­‐related  and  subject  to  considerable  inter-­‐pa-ent  variability”1  

–  “Intoxica-on  type  reac-ons  appear  dose-­‐related  due  to  great  inter-­‐pa-ent  drug  level  variability”  2    

–  “The  pharmacokine-c  data  show  great  inter-­‐subject  variability”3  

1) Marinol  Summary  Basis  of  Approval  2) Sa6vex  Product  Labelling  -­‐  Black  Box  Warning  3) Sa6vex  Product  Labelling  

NEMUS  prodrug  technology  designed  to  capitalize  on  the  use  of  proprietary  formulaIons  that  could  allow  for  alternaIve  delivery  methods  miIgaIng  risk  of  unpredictable  plasma  levels  that  can  compromise  safety  and  efficacy  

8  

InnovaIve  Cannabinoid  FormulaIons    Designed  for  Improved  Drug  Delivery  

-­‐    

•  Ocular  delivery:        Glaucoma  &  re-nal  diseases      •  Transmucosal  delivery:      CINV  &  CIPN  (suppository  &    

         buccal  patch)  

•  Transmembranous  delivery:    An--­‐infec-ves  (An--­‐MRSA)        (nasal/transdermal)  

All  NEMUS  licensed  delivery  opIons  opImize  our  prodrug  cannabinoid  technology  by  enhancing  bioavailability  by  avoiding  

first-­‐pass  liver  metabolism  and  offering  more  predictable  pharmacokineIcs  

9  

•  The  University  of  Mississippi  (UM)  is  the  only  enIty  in  the  US  authorized  by  NIDA  and  the  DEA  to  cul-vate  cannabis  on  behalf  of  the  federal  government  for  more  than  45  years  

•  NEMUS  has  exclusive,  perpetual,  worldwide  exclusivity  for  all  compounds  and  targets  we  are  working  on  with  UM  for  key  fields  of  delivery  

•  Patents  have  been  issued  for  the  proprietary  prodrug  of  THC  in  the  USA  (2014),  Japan  (2015)  and  Australia  (2016);  patents  pending  are  EU,  Canada,  and  Hong  Kong.  

•  A  recent  DEA  proposal  of  broadening  the  ability  of  universi-es  to  par-cipate  in  growing  cannabis  for  research  has  liGle  direct  impact  on  Nemus  given  the  underlying  patent  estates  licensed  by  the  Company  for  therapeuIc  development  of  cannabinoids  

•  Nemus  and  the  University  are  currently  engaged  in  the  development  of  third-­‐generaIon  hybrid  syntheIc  cannabinoid  molecules  with  the  goal  of  becoming  the  leading  developer  of  second-­‐  and  third-­‐generaIon  compounds  in  the  field  of  cannabinoid-­‐related  medicines  

Exclusive  strategic  relaIonship  with  the  University  of  Mississippi  provides  access  to  a  diverse  cannabinoid  patent  estate  

10  

Development  Pipeline:  OpImizing  THC  and  CBD  Delivery  Through  Unique  FormulaIons  

Drug  Name   Target   Delivery   Research   Pre-­‐clinical   Phase  1   Phase  2/3  

NB1222  (THC-­‐based)  

Chemotherapy-­‐induced  nausea  &  vomiIng  (CINV)  

Suppository  &  Buccal  Patch  

NB1111  (THC-­‐based)  

Glaucoma/Ophthalmology  Targets  

Sustained  Ocular  

NB2111  (CBD-­‐based)  

Chemotherapy-­‐induced  peripheral  neuropathy  (CIPN)  

Trans-­‐membranous  

ID  pending    

Methicillin-­‐Resistant  Staph  Aureus  (MRSA)    

Topical  &  Transdermal  

Target  indicaIons  are  mulI-­‐billion  dollar  global  markets  of  urgent  medical  need  

11  

 NB1222  

Treatment  of    Chemotherapy-­‐Induced    

Nausea  and  Vomi-ng  (CINV)        

12  

NB1222:  Chemotherapy-­‐Induced    Nausea  and  VomiIng  (CINV)  

•  There  are  an  es-mated  15  million  cancer  cases  globally  according  to  the  Interna-onal  Agency  for  Research  on  Cancer  

•  25%-­‐30%  of  pa-ents  receive  chemotherapy;  of  the  chemotherapy  recipients,  70%-­‐80%  experience  CINV  

•  The  global  CINV  market  exceeds  $1.3  B  

•  Dronabinol  is  an  orally  administered  synthe-c  version  of  THC  approved  for  cachexia  in  HIV  and  nausea/vomi-ng  in  CINV  with  annual  sales  for  CINV  in  excess  of  $110  MM  (Source:  IMS  Health)  

•  NEMUS  plans  to  iniIally  develop  a  suppository  version  of  our  proprietary  prodrug  of  THC,  NB  1222,  for  use  in  CINV  by  filing  an  NDA  via  the  expedited  regulatory  pathway  of  505(b)(2)  

13  

NB1222  Advantages  Versus  Dronabinol  in  CINV  

-­‐1  

4  

9  

PD   1   3   5   7   9   11   13   15   17   19   21   23  

Plasma  Co

ncen

traI

ons  (ng/

ml)  

Timepoint  (h)  

A  Comparison  of  THC  Plasma  ConcentraIons  From    ProDrug  THC  Suppository*  vs.  dronabinol  in  Humans  

Dronabinol  10  mg   THC  10  mgEg  

•  Bioavailability:  Dronabinol  has  been  found  to  have  a  bioavailability  of  6%-­‐15%  while  a  prodrug  of  THC  administered  via  suppository  yielded  a  bioavailability  of  roughly  70%*  

•  AbsorpIon:  Orally  administered  dronabinol  can  have  erra-c  absorp-on  from  the  gut  coupled  to  varying  plasma  levels  due  to  first-­‐pass  metabolism  in  the  liver;  a  suppository  avoids  the  upper  GI  tract  and  thereby  de-­‐risks  the  nega-ve  effect  of  first-­‐pass  metabolism  on  the  drug  pharmacokine-cs  

•  Adverse  Events:  Oral  dronabinol  has  been  associated  with  nausea  and  vomi-ng  adverse  events;  a  suppository  route  of  administra-on  mi-gates  that  side  effect  

•  PharmacokineIcs:  THC  prodrug  dosing  using  a  suppository  allows  greater  drug  exposure  (graph  above)  and  maintenance  within  the  therapeu-c  window  versus  peak/trough  PK  with  oral  dosing    

Source:    NEMUS  Internal  Data    

14  

NB1111  For  the  Treatment  of    

Glaucoma  

15  

The  Glaucoma  Market  

•  $8  billion  globally  and  growing  with  aging  popula-ons  •  A  leading  cause  of  blindness  in  the  US  •  $2.3  billion  US  market  (32  MM  Rx)  •  Regulatory  pathway  well-­‐defined  •  Regulatory  strategy:  Poten-al  for  “urgent  medical  need”  and  “breakthrough  therapy”  FDA  designa-ons;    

•  Glaucoma  as  a  “Non-­‐responder”  market  presents  greater  opportuni-es;  >50%  of  pa*ents  on  2  or  more  Rx  

•  Cannabinoids  have  shown  neuroprotec-ve  quali-es  in  vitro  and  in  vivo  (mul-ple  animal  species)  related  to  the  op-c  nerve  

•  Licensing  and  acquisiIons  in  the  glaucoma  market  occur  predominantly  earlier  in  development  (pre-­‐clin,  phase  1)  

16  

NB1111  (Glaucoma/Ophthalmology)  

Sustained  release  treatment  with  a  proprietary  THC  prodrug  could  bring  a  new  therapeuIc  class  directly  to  the  target  organ,  avoiding  systemic  exposure  

OCULAR  FEATURES  OF  NB1111  •  Penetrates  mul-ple  chambers  of  the  eye  •  Produces  a  45%  reduc-on  in  Intra-­‐Ocular  Pressure  (IOP)  in  glaucoma  animal  model  (THC  has  been  shown  to  lower  IOP  in  previous  human  tes-ng)  •  ReducIon  of  IOP  is  the  only  proven  method  to  manage  damage  to  the  op-c  nerve  in  glaucoma    •  Sustained  release  via  an  implantable  delivery  vehicle  to  enhance  compliance  is  being  explored  •  PotenIally  first  medicaIon  to  exert  direct  neuroprotec-on  of  the  op-c  nerve  (re-nal  ganglion  cells;  RGCs)  by  inhibi-ng  apoptosis  pathway    •  NeuroprotecIon  is  the  “holy  grail”  of  glaucoma  

The  proprietary  formulaIon  allows  THC  to  be  absorbed  across  membranes  that  are  normally  barriers  to  absorpIon    

17  

THCVHS  (prodrug)  vs  THC  IOP  reducIon  over  Ime  profile:  Prodrug  achieves  significant  decline  in  IOP  using  SLN  (solid  lipid  nanoparIcle)  technology  

18  

Superior  reducIon  in  IOP  by  THCVHS  versus  THC  explained  by  enhanced  Issue  penetraIon  into  organs  regulaIng  IOP  

•  THC  administered  in  an  SLN  showed  no  appreciable  concentra-on  in  ocular  -ssues  regula-ng  IOP  

•  THCVHS  (prodrug  of  THC)  shows  -ssue  penetra-on  into  ocular  organs  regula-ng  IOP  and  the  re-na  at  3  hours  post-­‐administra-on  

19  

THC  Can  Address  MulIple  MOAs  in  Lowering  IOP  and  Preserving  ReInal  Ganglion  Cells  (RGCs)  Therapy  Class        

 Mechanism  of  Ac-on  (MOA)  

 Increased  flow  trabecular  mesh  

Increased  flow  uveoscleral  pathway  

 Decreased  fluid  produc-on  

Direct  neuroprotec-ve  

quali-es  

Prostaglandins  (50%  mkt  share)  

X  

β-­‐  adrenergic  blockers  (30%)  

X  

α-­‐  adrenergic  agonists  (10%)  

X   X  

Carbonic  anhydrase  inhibitors  (<5%)  

 X  

Cholinergic  agonists  (<5%)  

X  

Pro-­‐drug  THC  (NB1111)  

X   X   X   X  

20  

THC  Lowers  IOP  in  Humans;  PredicIve  Animal  Model  Consistent  with  Human  Experience    

•  The  acIve  moiety  of  NB1111,  THC,  has    been  shown  to  lower  IOP  in  mul-ple  human  studies    •  THC  delivered  by  inhala-on  (smoking)  or  edible  lowered  IOP  40%  to  65%  but  compromises  blood  flow  to  re-na  via  systemic  vasodila-on  and  dosing  complicated  by  short  half-­‐life  

•  The  NEMUS  prodrug  NB1111  achieved  a  45%  reduc-on  in  IOP  in  validated  rabbit  glaucoma  model  tes-ng  conducted  at  UM    •  New  formulaIon  evaluaIon  of  NB1111  will  confront  the  compliance  issue  of  topical  drops  (eyedrops)  by  assessing  development  of  implantable  sustained  release  device  •  Current  eyedrop  data  using  SLN  technology  poin-ng  to  BID  dosing  

•  Next  stage  tesIng:  •  Human  studies  looking  at  IOP  lowering  effect  as  single  dose  and  mul--­‐dosages  

•  Possible  partnering  of  this  development  program  with  a  company  with  a  dedicated  presence  in  the  ophthalmology  space  

21  

CHEMOTHERAPY-­‐INDUCED  PERIPHERAL  NEUROPATHY  (CIPN)  

 CBD  DERIVATIVES  

22  

Chemotherapy-­‐Induced  Peripheral    Neuropathy  (CIPN):  Market  Data  •  CIPN  is  a  dose-­‐dependent  complica-on  associated  with  many  types  of    

chemotherapeu-c  agents  

•  In  addiIon  to  severe,  someImes  unremimng  pain,  it  can  also  lead  to  premature  discon-nua-on  of  chemotherapy.    

•  No  agents  have  been  shown  to  prevent  CIPN.  There  is  an  unmet  medical  need  for  therapies  that  can  mi-gate    pain  without  complica-ons  like  addicIon  and  gastrointesInal  obstrucIon  

•  The  CIPN  market  in  the  United  States  exceeds  $500  MM  (LifeSci  Advisors,  2013)  and  the  parallel  opioid-­‐induced  cons-pa-on  market  is  es-mated  to  be  $600  MM  globally  (GlobalData,  2015)  

•  The  overall  global  pain  market  is  projected  to  be  $35  billion  by  2017*  

•  The  market  is  searching  for  “abuse  resistant”  analgesic  alternaIves    *  GBI  Research:  Global  Pain  Markets,  2015  

23  

NB2111:  exhibits  significant  analgesia  

•  NEMUS  has  signed  a  research  agreement  with  UM  to  screen  mul-ple  CBD-­‐related  deriva-ves  in  validated  animal  models  of  CIPN  

•  NB2111  is  a  CBD-­‐like  molecule  that  has  been  tested  in  a  murine  model  of  tac-le  allodynia  replica-ng  the  neuropathy  associated  with  exposure  to  the  chemotherapeu-c  agent  of  cispla-n  (used  in  lung,  breast  and  colon  cancers)  

•  NB2111  resulted  in  significant  analgesia  in  this  model  with  coverage  commensurate    with  that  seen  using  the  highest  dose  of  morphine  exposure  

•  Next  steps  in  development  include  advancing  the  tes-ng  to  assess  maximum  tolerable  dose  in  animal  studies  and  developing  the  formula-on  of  the  compound  to  make  it  suitable  for  parenteral  and  non-­‐parenteral  dosing  

•  NEMUS  and  UM  will  con-nue  assessing  other  forms  of  CBD  deriva-ves  in  an  effort  to  develop  therapeuIc  opIons  for  mulIple  types  of  pain  syndromes  (e.g.  migraine)  and  possible  anI-­‐addicIve  uses  to  combat  the  global  opioid  addic-on  crisis  

 

24  

METHICILLIN-­‐RESISTANT  STAPHYLOCOCCUS  AUREUS  

   MULTIPLE  CANNABINOID  

DERIVATIVES  

25  

MRSA  Has  Become  a  Global  Urgent  Health  Concern  

26  

Methicillan-­‐Resistant  Staph  Aureus  (MRSA)  

MRSA  FACTS  &  CURRENT  MEDICAL  LANDSCAPE  •  First  described  in  1961  now  a  pandemic  •  CDC:  prevalence  of  MRSA  in  ICU  sexng  approaching  60%  •  1960’s:  one  gene-c  MRSA  muta-on/clone;  currently  six  MRSA  gene-c  clones;  15  clones  in  China  •  2010  hospital  survey:  61.8%  of  pa-ents  admiGed  to  ICU  were  MRSA  colonized1  

•  50%  of  screened  pa-ents  had  healthcare-­‐associated  infec-ons1  •  11,000  deaths  annually;  80,000  invasive  infec-ons/yr.2  •  Annual  costs  in  the  US:  $3.2  -­‐  $4  billion2  

 1)  Jarvis  WR  et  al;  Am  J  Infect  Control  2012;  40(3):  194-­‐200  2)  Pew  Trust  MRSA  Survey;  April  3,  2012  

27  

Methicillan-­‐Resistant  Staph  Aureus  (MRSA)  

NEMUS  is  Assessing  a  New  Class  of  AnI-­‐InfecIves  to  Combat  the  Threat  of  AnIbioIc  Resistance  

CANNABINOID  EXPERIENCE  IN  MRSA1  

•  Select  cannabinoids  have  been  known  to  possess  some  an-bacterial  proper-es  1    •  Nemus  has  successfully  screened  the  bactericidal  acIvity  of  a  library  of  individual  cannabinoids  against  mulIple  strains  of  MRSA  •  Nemus  has  iden-fied  cannabinoid  cocktails  with  significant  synergisIc  bactericidal  acIvity  against  MRSA  •  Nemus  intends  to  assess  the  ac-vity  of  a  library  of  syntheIc  cannabinoid  molecules  to  treat  MRSA  with  the  goal  to  broaden  the  IP  estate  •  Nemus  an-cipates  partnering  the  gram-­‐posi-ve  an--­‐microbial  playorm  in  the  H1’2017  -meframe  to  accelerate  development  of  these  compounds  

 

1)  J  Nat  Prod.  2008  Aug;71(8):1427-­‐30.  doi:  10.1021/np8002673.  Epub  2008  Aug  6.    -­‐  An-bacterial  cannabinoids  from  Cannabis  sa-va:  a  structure-­‐ac-vity  study  

28  

NEMUS  Bioscience,  Inc.  (OTCQB:  NMUS)  

•  NEMUS  is  focused  on  developing  cannabinoid  molecules  for  the  treatment  and  management  of  acute  and  chronic  diseases,  especially  those  of  unmet  medical  need  

•  NEMUS  cannabinoid  molecules  are  engineered  to  enhance  trans-­‐membrane  transport  resulIng  in:  ü  Enhanced  bioavailability  ü  Permits  routes  of  administra6on  that  avoid  first-­‐pass  metabolism  by  the  liver  ü  Resul6ng  in  more  predictable  pharmacokine6cs  ü  Patent  issued  in  August,  2014  allows  long  IP  runway  with  broad  claims  and  reach  for  

the  delivery  of  molecules  and  condi6ons  that  can  be  treated  

•  NEMUS  is  the  sole  development  and  commercializaIon  partner  of  the  University  of  Mississippi,  drawing  on  47  years  of  intellectual  capital  in  cannabinoid  chemistry  and  physiology  

•  NEMUS  is  advancing  therapeuIcs  for  medical  applica-ons  in  global  mul--­‐billion  dollar  markets  including  a  cannabinoid  franchise  in  ophthalmology,  palliaIve  care  in  oncology,  and  anI-­‐infecIve  medicines,  especially  in  strains  developing  resistance  to  an-bio-cs  

29  

Management  

BRIAN  MURPHY,  MD,  MPH,  MBA  –  Chief  ExecuIve  Officer;  Chief  Medical  Officer,  Director  Dr.  Murphy  has  almost  two  decades  of  experience  in  drug  development  and  evalua-on,  both  from  the  academic  and  industry  perspec-ve.   He   most   recently   served   as   the   CMO   of   Eiger   Biosciences.   Previously,   Dr.   Murphy   was   CMO   at   Valeant  Pharmaceu-cals   Interna-onal   (VRX)   where   his   responsibili-es   also   included   oversight   of   Global   Medical   Affairs   and  Pharmacovigilance.  Dr.  Murphy  also  served  as  Medical  Director,  then  VP  of  Marke-ng  and  Commercial  Strategy  of  Hepatology  for  InterMune,  Inc.  (ITMN).  Prior  to  InterMune,  Dr.  Murphy  was  Medical  Director  of  North  America  for  An-virals/Interferons  at  Hoffmann-­‐LaRoche.  Murphy  is  board-­‐cer-fied  in  internal  medicine  and  completed  his  residency  at  Tuzs-­‐New  England  Medical  Center.  He  went  on  to  complete  parallel  fellowship  tracts  at  Harvard  Medical  School  and  the  MassachuseGs  General  Hospital.  Dr.  Murphy  earned  his  MD,  MPH  (general  public  health),  and  MS  (pharmacology)  degrees  from  New  York  Medical  College  and  is   a   graduate   of   the   Harvard   School   of   Public   Health   (MPH   in   Health   Policy   and  Management).   He   earned   his  MBA   at   the  Columbia  University  Graduate  School  of  Business.    

   LIZ  BERECZ,  MA,  CPA  -­‐  Chief  Financial  Officer  Elizabeth  Berecz  is  a  seasoned  financial  execu-ve  with  over  20  years  of  experience  holding  senior  level  posi-ons  in  both  private  and   public   companies.   She   has   proven   success   in   leading   strategic   planning,   financial   repor-ng,   and   global   system  implementa-ons  for  companies  of  various  sizes.  Liz  started  her  career  at  Price  Waterhouse  Silicon  Valley  where  she  spent  five  years  audi-ng  several  high  profile  public  companies  in  the  technology  industry.  She  then  spent  10  years  holding  key  leadership  posi-ons   in   various   publicly   held   Companies   including   Quantum   Corpora-on   (Corporate   Controller),   Business   Objects   (VP  Finance  and  Administra-on),  and  Excite  (VP  Finance),  followed  by  10  years  of  key  leadership  roles  in  privately  held  Companies  including   CFO   posi-ons  with   Op-cal   Shop   Interna-onal,   StarTrac   Inc.,   Power   Balance   Technologies,   Inc.   and  most   recently  Bentley   Mills,   Inc.   She   also   serves   as   an   Adjunct   Professor   of   Accoun-ng   and   Finance   at   the   University   of   San   Francisco.  Elizabeth   received   her   BA   in   Economics   from   Stanford   University   and   a  MA   in   Sports  Management   from  University   of   San  Francisco.    

30  

Management  

COSMAS  N.  LYKOS,  ESQ  –  Co-­‐founder,  Officer  &  Board  Member  –  ExecuIve  Chairman      Cosmas  Lykos  co-­‐founded  NEMUS   in  2012  and  has  served  as   its  Chairman  of   the  Board  of  Directors   since  August  2014.    Azer  gradua-ng  with  Honors  from  Duke  University  School  of  Law  in  1993,  Mr.  Lykos  began  his  career  at  Gibson  Dunn  &  Crutcher,  LLP,  an   interna-onal   full-­‐service   law  firm,  as  a  corporate  associate  un-l  1998.    From  1998  to  2004,  Mr.  Lykos  served  as  Vice  President  of  Business  Affairs,  General   Counsel,   Secretary   and  Chief  Compliance  Officer  of  RemedyTemp,  Inc.,  a  NASDAQ  publicly-­‐traded  temporary  staffing  firm  with  over  250  directly-­‐owned  and  franchised  offices  na-onwide.    From  2004  un-l  2008,  Mr.  Lykos  served  as  Vice  President  of  Business  Development,  Chief  Legal  Officer,  Secretary  and  Chief  Compliance  Officer  of  Oakley,   Inc.,   a  NYSE  publicly-­‐traded   sports  and   technical  eyewear,   apparel,   accessories  and   retail  company.     In   January   of   2008,   he   became   Co-­‐owner   and   President   of   the   Op-cal   Shop   Interna-onal,   a   designer   and  distributor   of   licensed   eyewear   brands,   including   Chrome   Hearts   and   Blinde,   through   two   wholly-­‐owned   foreign  subsidiaries  with  a  direct  and  distributor  sales  network   in  over  60  countries  around  the  world.    Primary   responsibili-es  included  developing  and  implemen-ng  OSI’s  vision  and  strategies  and  the  management  of   its  foreign  subsidiaries,  sales,  legal,  human  resources,  finance  and  administra-ve  func-ons.    In  2011,  Mr.  Lykos  nego-ated  and  consummated  the  sale  of  OSI  to  its  primary  licensor,  Chrome  Hearts  LLC  and  con-nues  to  provide  consul-ng  services.    Mr.  Lykos  has  extensive  public  and  private  company  board  of  directors  experience.    As  Chief  Compliance  and  Legal  Officer  and  Secretary  of  both  Oakley,  Inc.  and  RemedyTemp,  Inc.,  Mr.  Lykos  aGended  all  board  of  director  mee-ngs  and  board  commiGee  mee-ngs.    As  an  angel  investor,   Mr.   Lykos   has   made   minority   investments   in   various   private   companies   and   has   served   on   their   Board   of  Directors.      

31  

BOD  &  Strategic  Advisors  

MAHMOUD  A.  ELSOHLY,  PHD    ScienIfic  Advisor  World’s  foremost  expert  on  the  science  of  cannabinoids.    300+    scien-fic  publica-ons  .    Research  professor  at  The  University  of  Mississippi.  

JERRY  MCLAUGHLIN,  MBA    Strategic  Advisor,    Board  of  Directors  -­‐  Member  CEO  of  AgeneBio;  25  year  veteran  execu-ve  in  pharmaceu-cal  medical  device  and  healthcare  related  industries  (Endo  Pharma,  Merck,  MBA-­‐  Villanova  University,BA-­‐  Dickinson  College).  

TOM  GEORGE  Board  of  Directors  –  Chairman  of  Audit  Commisee  

30  year  senior  execu-ve  in  corporate  finance  and  accoun-ng;  CFO  of  Deckers  Brands  (  Ophthonix,  Oakley,  Coopers  &  Lybrand).  Graduate  of  University  of  Southern  California.  

DOUGLAS  S.  INGRAM,  ESQ  Board  of  Directors  –  Vice  Chairman,  Chairman  of  CompensaIon  Commisee  25  year  senior  execu-ve  in  healthcare,  Past  President  of  Allergan,  former  AGorney  at  Gibson,  Dunn  &  Crutcher,  LLP.  Summa  cum  laude  and  Order  of  the  Coif  graduate  of  the  Univ.  of  Arizona  school  of  law.  

DONALD  I.  ABRAMS,  M.D.    ScienIfic  Advisor  Chief,  Hematology/Oncology  at  UCSF  Cancer  and  Integra-ve  Medicine  specialist  with  research  interests  in  the  development  of  an--­‐cancer  therapeu-cs  and  pallia-ve  care  medicines.  

32  

Contact  

 650  Town  Center  Drive,  Suite  1770  

Costa  Mesa,  CA  92626  949-­‐396-­‐0330  

hello@nemusbio.com  www.nemusbioscience.com    

Investor  RelaIons:  Adam  Holdsworth  PCG  Advisory  Group  Tel:  646-­‐862-­‐4607  adamh@pcgadvisory.com    

Company:  Brian  Murphy,  MD,  MPH,  MBA  CEO  -­‐  CMO  Tel:  949-­‐355-­‐1140  brian@nemusbio.com